Improved Survival After Stem Cell Transplant from Mismatched Donors
A study shows that patients receiving stem cell transplants from HLA-mismatched unrelated donors can achieve strong survival outcomes with post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease prevention.